Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: David M. Gloss who wrote (4693)	12/16/1999 11:19:00 AM
From: OLD JAKE JUSTUS	Read Replies (1) \| Respond to of 4891

Thank you, Sir! Free Edgar notified me of all of that yesterday, but I have not had the spare time to read it, yet. Many thanks!

To: David M. Gloss who wrote (4693)	12/16/1999 6:39:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4891

ADVANCED VIRAL RESEARCH CORP has filed a Form 424B3 (Prospectus Filed Pursuant to Rule 424) with the United States Securities and Exchange Commission. Click on the following hyperlink to view this filing: freeedgar.com PROSPECTUS SUMMARY This summary highlights information about the offering and Advanced Viral Research Corp. which we believe will be most important to you. However, you should read the entire prospectus for a complete understanding of the offering and our business. Advanced Viral Research Corporation Advanced Viral is a development stage company formed to engage in the production and marketing, promotion and sale of the pharmaceutical product Reticulose(Trademark) for the treatment of certain viral diseases such as: o human immunodeficiency virus, or HIV, including acquired immune deficiency syndrome, or AIDS; o hepatitis B and hepatis C, both liver diseases o human papilloma virus, or HPV, which causes genital warts and may lead to cervical cancer; o rheumatoid arthritis. Since 1962, when Reticulose was reclassified as a "new drug" by the FDA, the FDA has not permitted Reticulose to be marketed in the United States. A forfeiture action was instituted in 1962 by the FDA against Reticulose, and Reticulose was withdrawn from the United States market. The injunction obtained by the FDA prohibits, among other things, any shipment of Reticulose until a new drug application, or NDA, for Reticulose is approved by the FDA. FDA approval of an NDA first requires clinical testing of Reticulose in human trials, which cannot be conducted until we first satisfy the regulatory protocols and the substantial preapproval requirements imposed by the FDA upon the introduction of any new or unapproved drug product pursuant to a notice of claimed investigational exemption for a new drug, or IND. Our operations over the last five years have been limited principally to research, testing and analysis of Reticulose in the United States, either in vitro (outside the living body in an artificial environment, such as in a test tube), or on animals, and engaging others to perform testing and analysis of Reticulose on human patients outside the United States. Shalom Z. Hirschman, M.D., our President, has monitored the testing of Reticulose and has recently performed analyses of Reticulose with our laboratory personnel, which we believe may be used in connection with the FDA approval process. In addition, we have recently contracted with GloboMax LLC of Hanover, Maryland to advise us in our preparation and filing of an IND with the FDA, and to otherwise assist us through the FDA process with the objective of obtaining full approval for the manufacture and commercial distribution of Reticulose in the United States. Our offices are located at 1250 East Hallandale Beach Boulevard, Suite 501, Hallandale, Florida 33009 and 200 Corporate Boulevard South, Yonkers, New York 10701. Our telephone number in Hallandale, Florida is (954) 458-7636 and our telephone number in Yonkers, New York is (914) 376-7383.